FluoGuide A/S (FLUO.ST)
FluoGuide A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Copenhagen, CR, DK. The stock last traded at $35.10, up 0.29% on the session, giving a market capitalisation of $573.9M. Its beta of 1.00 implies it has historically moved more than the broad market.
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.
FluoGuide A/S is most often compared with the following Healthcare names: